# A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer

> **NCT03560856** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 54 (estimated)

## Conditions studied

- Breast Cancer
- HR+/HER2-negative Breast Cancer
- Metastasis

## Interventions

- **DRUG:** Fulvestrant + palbociclib

## Key facts

- **NCT ID:** NCT03560856
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-27
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2018-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03560856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03560856, "A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03560856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*